Baricitinib bumped up filaggrin and loricrin gene expression in an IL-23-driven psoriasis-like dermatitis model, according to a paper that went online 25 September 2026 in the Journal of Dermatological Science.

The work comes from Sydney Kenney, Xuesong Wu, Hinako Saito, Scott Simon and Sam T. Hwang. Their title — "Baricitinib Upregulates Filaggrin and Loricrin Gene Expression in IL-23-Driven Psoriasis-like Dermatitis" — tells readers two things up front: the signal goes up, and the model is mechanistic rather than clinical.

Why the two genes matter

Filaggrin pulls keratin filaments together and degrades into natural moisturizing factor. Loricrin anchors the cornified envelope.

Both proteins are known to fall in lesional psoriatic skin. That drop tracks with the visible scale and the barrier defect patients describe.

Restoring them has long been a quiet side goal of psoriasis therapy — separate from the headline chase after PASI 100. The gap helps explain why patients reach for ceramide creams on the way out the door even after a biologic clears the plaques.

What the paper does, and what it doesn't

Kenney and colleagues work in an IL-23-driven dermatitis model — the workhorse preclinical platform for psoriasis research that mimics the IL-23/IL-17 axis without patients. Intradermal IL-23 injections reproduce the keratinocyte hyperproliferation, neutrophil microabscesses and acanthosis that define the human disease. That makes the model a fast, cheap first filter for any drug the field wants to push toward plaques.

The title confirms direction of effect (upregulation) and the read-out (gene expression). It does not disclose effect size, dose, or duration.

Nor does it say whether the messenger-RNA signal carried through to protein or histology. Readers should wait for the methods and figures to translate the headline into a number.

How baricitinib fits into today's psoriasis conversation

Baricitinib is a JAK1/JAK2 inhibitor with FDA-approved dermatology indications in moderate-to-severe atopic dermatitis and severe alopecia areata — not plaque psoriasis.

Tofacitinib, upadacitinib, abrocitinib and ritlecitinib have done similar work in adjacent indications, from atopic dermatitis to alopecia areata to hidradenitis suppurativa. Each cleared a cytokine and quietly raised the same question: does the cornified envelope come along for the ride?

A mechanistic paper in an IL-23 model therefore reads as hypothesis-generating, not as a label expansion. A signal that a JAK inhibitor can lift two barrier-protein genes in a Th17-skewed model nudges the conversation back toward structural repair.

What does this change for clinicians?

Not much this quarter. The drug isn't indicated for psoriasis, the model is preclinical, and the readout stops at messenger RNA.

What it does change is the question set. The next plausible trial isn't baricitinib monotherapy versus a biologic — it's baricitinib layered on top of an IL-23 blocker, with barrier function as a secondary endpoint. That's the slot to watch.

Combination strategy isn't new in dermatology. IL-23 plus a topical steroid is standard for stubborn plaques, and the psoriasis field has flirted with JAK-plus-biologic pairings in small investigator-initiated studies.

What hasn't happened is a registrational-grade, randomized design that asks whether blocking IL-23 upstream and tuning JAK downstream simultaneously buys a more durable, barrier-intact remission. That's the design slot this paper quietly opens.

Two barrier genes, one JAK inhibitor, one IL-23 model — and a question the field hasn't fully answered. The methods and the figures will decide how loudly this one echoes. Until then, treat the paper as a marker on the map, not a destination.